深圳市卫光生物制品股份有限公司 2022 年第三季度报告 证券代码：002880 证券简称：卫光生物 公告编号：2022-057 深圳市卫光生物制品股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 1 深圳市卫光生物制品股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |------------------------------------------------------|------------------|------------------------- ...

深圳市卫光生物制品股份有限公司 2022 年半年度报告 2022 年 8 月 第 1 页 共 106 页 深圳市卫光生物制品股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 董事、监事、高级管理人员是否存在对半年度报告内容存在异议或无法保证 其真实、准确、完整的情况 □是 否 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人 张战 、主管会计工作负责人 岳章标 及会计机构负责人 (会计主管人员) 黄悝 声明：保证本半年度报告中财务报告的真实、准确、 完整。 是否存在部分董事未亲自出席审议本次半年报的董事会会议的情形 □是 否 所有董事均已出席了审议本报告的董事会会议。 非标准审计意见提示 □适用 不适用 对半年度报告涉及未来计划等前瞻性陈述的风险提示 适用 不适用 本半年度报告内涉及的未来计划、发展战略等前瞻性陈述不构成公司对 投资者的实质承诺，投资者及相关人士均应对此保持足够的风险认识，并且 应当理解计划、预测与承诺之间的差异。请投资者注意投资风险。 第 2 页 共 1 ...

深圳市卫光生物制品股份有限公司 2022 年第一季度报告 □ 是 √ 否 证券代码：002880 证券简称：卫光生物 公告编号：2022-028 深圳市卫光生物制品股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告 中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|-----------------------------| | | ...

深圳市卫光生物制品股份有限公司 2022 年第一季度报告 □ 是 √ 否 证券代码：002880 证券简称：卫光生物 公告编号：2022-028 深圳市卫光生物制品股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告 中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|---------------------------| | | 本 ...

深圳市卫光生物制品股份有限公司 2021 年年度报告 深圳市卫光生物制品股份有限公司 2021 年年度报告 2022 年 4 月 第 1 页 共 145 页 深圳市卫光生物制品股份有限公司 2021 年年度报告 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人张战、主管会计工作负责人岳章标及会计机构负责人(会计主管 人员)黄悝声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告内涉及的未来计划、发展战略等前瞻性陈述不构成公司对投资 者的实质承诺，投资者及相关人士均应对此保持足够的风险认识，并且应当理 解计划、预测与承诺之间的差异。请投资者注意投资风险。 公司在本报告"第三节 管理层讨论与分析"之"十一、公司未来发展的展 望"部分详细描述了公司未来经营中可能存在的主要风险，敬请广大投资者予 以关注并注意投资风险。 公司经本次董事会审议通过的利润分配预案为：以 226,800,000 股为基数， 向全体股东每 10 股派 ...

深圳市卫光生物制品股份有限公司 2021 年第三季度报告 证券代码:002880 证券简称:卫光生物 公告编号:2021-057 深圳市卫光生物制品股份有限公司 2021年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1、董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2、公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季 度报告中财务信息的真实、准确、完整。 3、第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |------------------------------------------------------|----------------|------------------------|----------------|--------------- ...

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 335,788,141.61, a decrease of 17.61% compared to CNY 407,556,862.46 in the same period last year[32]. - The net profit attributable to shareholders of the listed company was CNY 69,960,029.07, down 9.73% from CNY 77,500,387.25 in the previous year[32]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 65,914,936.94, a decrease of 11.57% compared to CNY 74,538,412.22 last year[32]. - The net cash flow from operating activities was CNY 44,354,483.29, a significant decline of 77.17% from CNY 194,322,683.37 in the same period last year[32]. - Basic earnings per share were CNY 0.3085, down 35.16% from CNY 0.4758 in the previous year[32]. - Total assets at the end of the reporting period were CNY 1,796,231,288.84, a decrease of 2.17% from CNY 1,836,144,030.49 at the end of the previous year[32]. - The net assets attributable to shareholders of the listed company increased by 1.84% to CNY 1,633,248,868.93 from CNY 1,603,788,839.86 at the end of the previous year[32]. - The company's gross profit margin improved as operating costs decreased by 23.25% to ¥199,846,790.10 from ¥260,391,640.47[84]. - The company reported a net cash flow from operating activities of ¥44,354,483.29, a significant decrease of 77.17% compared to ¥194,322,683.37 in the previous year[84]. - The company’s financial expenses increased by 157.53% to -¥4,432,718.02, primarily due to increased deposit interest[84]. Operational Highlights - In the first half of 2021, the company achieved operating revenue of 336 million yuan and a net profit attributable to shareholders of 70 million yuan[42]. - The company added 12,295 new plasma donors during the reporting period, a year-on-year increase of 3,434 donors, and completed plasma collection of 215 tons[43]. - The company maintained a 100% pass rate for GMP inspections, indicating strong product quality control[44]. - The company achieved a 100% batch release qualification rate for its products, ensuring safety and effectiveness throughout the production process[60]. - The company completed its plasma collection target for the first half of the year, maintaining a leading position in the industry with stable growth in its Waning plasma station[60]. - The company has established 8 single plasma collection stations, with the number of plasma donors and collection volume reaching new highs during the reporting period[73]. - The company holds 21 approved specifications across three major categories of blood products, with a high plasma utilization rate due to advanced production methods[74]. Market and Industry Insights - The actual plasma demand in China is estimated to exceed 14,000 tons, while the total plasma collection in 2020 was over 8,300 tons, indicating a significant supply-demand gap[65]. - The blood products industry is characterized by high barriers to entry and strict regulations, with a decreasing number of approved production enterprises[66]. - The global blood products market is highly concentrated, with the top five companies holding approximately 85% of the market share[63]. - The domestic blood products market is expected to grow due to increasing clinical demand and an aging population, despite a current supply shortage[66]. Research and Development - The human coagulation factor VIII is nearing completion of phase III clinical trials, with plans to submit a new drug application within the year[46]. - Research and development investment increased by 10.37% to ¥20,078,809.70, compared to ¥18,191,716.09 in the previous year[84]. - The company is committed to improving its R&D project management to align with market trends and reduce the risk of product development delays[110]. Sales and Marketing Strategies - The company is focusing on enhancing its sales channels and academic promotion efforts to drive product sales to new heights[58]. - The company is adopting aggressive sales policies and increasing academic investments to expand market reach amid intensified competition in blood products[110]. - The company successfully opened the market for its products in tier-three hospitals domestically, while also exporting key products to Venezuela and Brazil, marking a successful entry into international markets[60]. Environmental and Social Responsibility - The company reported a total wastewater discharge of 22,208 tons, with a permitted discharge limit of 173.2 tons per day, indicating compliance with environmental standards[125]. - The company operates two emission outlets for boiler exhaust, with nitrogen oxides measured at 35 mg/m³, adhering to the national emission standards[125]. - The company has committed to social responsibility initiatives, raising 32,705 yuan for various charitable activities during the reporting period[144]. - The company has established comprehensive environmental management systems, including wastewater treatment, to ensure compliance with environmental laws and regulations[145]. - The company emphasizes employee welfare, providing regular health checks and a supportive work environment[140]. Governance and Shareholder Relations - The company has established a robust governance structure to protect shareholder rights and ensure transparent information disclosure[139]. - The total number of ordinary shareholders at the end of the reporting period was 10,963, with significant shareholders including the State-owned Assets Supervision and Administration Commission holding 65.25%[191]. - The top ten unrestricted ordinary shareholders held a total of 172,000,000 shares, with the largest shareholder owning 147,987,000 shares[192]. - The company has not distributed cash dividends or bonus shares for the half-year period[115]. - The first phase of the employee stock ownership plan was completed with the purchase of 390,900 shares at an average price of RMB 51.515 per share, totaling RMB 20.14 million[119]. Compliance and Risk Management - The company plans to enhance its quality management system in response to compliance risks in the blood products industry, which is highly regulated by the government[106]. - The company has implemented a three-tier safety management system to mitigate risks associated with production safety accidents[107]. - The company is facing potential risks due to the COVID-19 pandemic affecting plasma collection, which may lead to temporary suspension of operations[108]. - There were no significant lawsuits or arbitration matters during the reporting period[156]. - The company did not experience any non-operating fund occupation by controlling shareholders or related parties during the reporting period[152].

深圳市卫光生物制品股份有限公司 2021 年第一季度报告全文 深圳市卫光生物制品股份有限公司 2021 年第一季度报告 2021 年 04 月 1 深圳市卫光生物制品股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人张战、主管会计工作负责人刘现忠及会计机构负责人(会计主管 人员)黄悝声明：保证季度报告中财务报表的真实、准确、完整。 2 深圳市卫光生物制品股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|---------------------------| | □ 是 √ ...

Financial Performance - The company reported a total revenue of RMB 1.62 billion for the year 2020, representing a year-on-year increase of 15%[18]. - The net profit attributable to shareholders was RMB 320 million, an increase of 20% compared to the previous year[18]. - The company's operating revenue for 2020 was ¥904,564,669.80, representing a 10.12% increase compared to ¥821,469,063.68 in 2019[26]. - The net profit attributable to shareholders for 2020 was ¥190,398,598.11, an increase of 11.12% from ¥171,344,660.74 in 2019[26]. - The net cash flow from operating activities reached ¥303,957,547.40, marking a significant increase of 63.68% from ¥185,701,134.80 in 2019[26]. - The company’s net profit attributable to shareholders increased by 10.77% to 1.60 billion yuan[62]. - The company achieved a revenue of 905 million yuan, representing a year-on-year growth of 10.12%[45]. - The net profit for the period was 190 million yuan, reflecting a year-on-year increase of 10.77%[45]. Dividends and Shareholder Returns - The company plans to distribute a cash dividend of RMB 2.5 per 10 shares, totaling approximately RMB 40.5 million[7]. - The cash dividend payout ratio for 2020 was 21.27% of the net profit attributable to ordinary shareholders[144]. - The company plans to distribute a cash dividend of 2.5 yuan per 10 shares, totaling 40,500,000 yuan, which represents 38.46% of the distributable profit[145]. - The cash dividend distribution is in compliance with the minimum requirement of 20% for cash dividends during significant capital expenditure phases[145]. Market Expansion and Growth Strategy - User data indicates a growth in the number of active users by 25% year-on-year, reaching 1.5 million[18]. - The company is focusing on expanding its market presence, with plans to open 10 new plasma collection stations in 2021[18]. - The company is exploring potential acquisition opportunities to further strengthen its market position[18]. - The company is actively exploring international markets and enhancing academic investments to stimulate market expansion and new opportunities[132]. - The company aims to increase sales of key products such as rabies immunoglobulin and tetanus immunoglobulin, while also enhancing distributor cooperation to meet sales and profit targets[124]. Research and Development - Research and development expenses increased by 30% to RMB 150 million, reflecting the company's commitment to innovation[18]. - The company has established a specialized biotechnology innovation center and industrial park to enhance its research and development capabilities[128]. - The company has 36 patents and a highly educated R&D team, with 94.7% of R&D personnel holding at least a bachelor's degree[55]. - The company has initiated clinical research for new products, including a new type of intravenous immunoglobulin (10%) and human fibrin adhesive[62]. Production and Quality Management - The company maintained a 100% batch release qualification rate for its products, ensuring safety and effectiveness[45]. - The production volume exceeded 370 tons, with a focus on refined management and cost reduction[47]. - The company is committed to optimizing GMP management processes to ensure product quality and compliance with national standards[125]. - The company achieved a 100% pass rate for self-inspection and batch release inspections during the reporting period, with no quality safety incidents reported[51]. Financial Management and Investments - The total investment amount for the reporting period was 203,193,040.46 CNY, a 97.38% increase compared to the previous year[94]. - The company has fully repaid bank loans amounting to CNY 18,500 million, achieving 100% investment progress[104]. - The company’s financing cash inflow increased significantly by 1,220.69% to ¥280,000,000.00[87]. - The net cash flow from investment activities increased by 101.03% year-on-year, primarily due to increased phase investments in the science park project[88]. Compliance and Risk Management - The company faces compliance risks due to high regulatory scrutiny in the blood products industry, which could impact production and profitability if regulations change[132]. - There is a potential risk related to product safety, despite advanced technology and management systems in place to ensure quality and safety during production[132]. - The company has implemented measures to enhance safety management and reduce risks associated with production accidents[132]. Corporate Governance and Social Responsibility - The company emphasizes its core values of integrity, innovation, and people-oriented principles in fulfilling social responsibilities[200]. - The company has established a robust corporate governance structure to protect shareholder and creditor rights[200]. - The company actively participates in social welfare projects and has established a volunteer service team[200].

深圳市卫光生物制品股份有限公司 2020 年第三季度报告全文 深圳市卫光生物制品股份有限公司 2020 年第三季度报告 2020 年 10 月 1 深圳市卫光生物制品股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及除以下存在异议声明的董事、监事、高级管理人员 外的其他董事、监事、高级管理人员均保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 董事、监事、高级管理人员异议声明 姓名 职务 内容和原因 所有董事均已出席了审议本次季报的董事会会议。 公司负责人张战、主管会计工作负责人刘现忠及会计机构负责人(会计主管 人员)黄悝声明：保证季度报告中财务报表的真实、准确、完整。 2 深圳市卫光生物制品股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------|------------- ...